RenovoRx, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $61.8M
- Price
- $1.37
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.44%
- Volume
- 594.6K
About
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.
Quick stats
Shares outstanding45.1M
Computed float35.3M
Float / shares78.3%
Cash runway (months)5.5
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001574094
Websitehttps://renovorx.com
AI Summary
AI-generated1/26
minorbullishclinical trial
RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial
RenovoRx enrolled the first patient in PRISM-TAMP, an investigator-initiated trial sponsored by the University of Vermont testing gemcitabine delivered via TAMP before surgery in borderline resectable pancreatic cancer.
UVM plans to enroll approximately 10 patients (NCT07477418), assessing tumor regression, surgical margin impact, and safety. This is the first RenovoRx-supported IIT to reach patient enrollment.
The trial is capital-efficient validation of TAMP beyond locally advanced PDAC, while the pivotal Phase III TIGeR-PaC readout remains the key catalyst, expected in the second half of 2027.